Showing 5551-5560 of 5643 results for "".
- Ophthalmologists Issue Eye Safety Warning Ahead of Fireworkshttps://modernod.com/news/ophthalmologists-issue-eye-safety-warning-ahead-of-fireworks-severy-year-about-10000-people-are-rushed-to-the-emergency-department-for-fireworks-injuries-ophthalmologists-physicians-who-s/2480108/Every year, about 10,000 people are rushed to the emergency department for fireworks injuries. Ophthalmologists treat thousands of patients who suffer a range of fireworks-related injuries, from cuts and bruises to damaged corneas, retinas, and ruptured eyeballs. Many people believe that consumer
- Ophthalmic OR Microscope Market to See More Than 6 Percent Growth over Next Five Yearshttps://modernod.com/news/ophthalmic-or-microscope-market-to-see-more-than-6-percent-growth-over-next-five-years/2480110/Market Scope expects the global ophthalmic operating room (OR) microscope market to grow at a healthy pace of more than 6 percent over the next 5 years, as 2018 revenues of $403 million climb to nearly $548 million by 2023. Revenues will rise most sharply in Latin America and other develop
- Ultrasonic Phaco Remains Dominant, but New Technologies Ready to Challengehttps://modernod.com/news/ultrasonic-phaco-remains-dominant-but-new-technologies-ready-to-challenge/2480114/Market Scope expects surgeons to perform nearly 18.5 million phaco procedures globally in 2018, and dedicated packs and accessories will make up more than 72 percent of the $1.6 billion in global cataract equipment revenues. Two factors will fuel modest growth in the cataract equipment mar
- Group of Takeda Shareholders Call Proposed Shire Purchase “Height of Madness”https://modernod.com/news/group-of-takeda-shareholders-call-proposed-shire-purchase-height-of-madness/2480115/A group of Takeda shareholders have criticized the company’s deal to buy Shire as “the height of madness,” raising concerns over the level of debt that will need to be taken on to fund the purchase, the Financial Times reported. The group hold just over 1 percent of Takeda’
- Orasis Pharmaceuticals Closes $13 Million Series B Financinghttps://modernod.com/news/orasis-pharmaceuticals-closes-13-million-series-b-financing/2480119/Privately-held Orasis Pharmaceuticals announced the closing of a $13 million Series B financing to be used to advance Orasis’s lead product candidate, CSF-1, an eye drop being developed for the treatment of presbyopia symptoms, through completion of its phase 2b clinical trial. The proceeds will
- Tobii and Lumus Bring Eye Tracking Technology to Augmented Reality Eyewearhttps://modernod.com/news/tobii-and-lumus-bring-eye-tracking-technology-to-augmented-reality-eyewear/2480121/At the Augmented World Expo (AWE) this week, Tobii announced that it is working with Lumus, a provider of transparent displays for augmented reality (AR), to incorporate eye tracking technology as part of the Lumus DK50 AR development kit.
- Caution Needed With Artificial Intelligence in Medicine, Experts Warnhttps://modernod.com/news/caution-needed-with-artificial-intelligence-in-medicine-experts-warn/2480125/Current hype surrounding machine learning and artificial intelligence (AI) in medicine is enormous, with seemingly daily headlines declaring that some new model will change how a disease is diagnosed or treated. Experts are more cautious, though, with several speakers at the recent
- FDA Approves First Artificial Irishttps://modernod.com/news/fda-approves-first-artificial-iris/2480126/The FDA approved the first stand-alone prosthetic iris in the United States, a surgically implanted device to treat adults and children whose iris is completely missing or damaged. “Patients with iris defects may experience severe vision problems, as well as dissatisfaction with the appear
- NTC to Strengthen Its Ophthalmology Portfolio Through the Acquisition of Ocular Antibiotic Productshttps://modernod.com/news/ntc-to-strengthen-its-ophthalmology-portfolio-through-the-acquisition-of-ocular-antibiotic-products/2480127/The Italian pharmaceutical company NTC announced the acquisition of some Novartis ocular antibiotic products, including broad spectrum antibiotic therapies to treat eye diseases. Countries covered under the agreement include Spain, Portug
- Trump Says Drug Companies to Unveil Price Cuts in Two Weekshttps://modernod.com/news/trump-says-drug-companies-to-unveil-price-cuts-in-two-weeks/2480129/Major pharmaceutical companies will announce “voluntary, massive” cuts in drug prices in two weeks, President Donald Trump said Wednesday, without providing details, according to a